Locally recurrent rectal cancer: Oncological outcomes for patients with a pathological complete response after neoadjuvant therapy

被引:8
作者
Nordkamp, Stefi [1 ,2 ,9 ]
Piqeur, Floor [3 ,4 ]
van den Berg, Kim [5 ]
Tolenaar, Jip L. [1 ]
van Hellemond, Irene E. G. [5 ]
Creemers, Geert-Jan [5 ]
Roef, Mark [6 ]
van Lijnschoten, Gesina [7 ]
Cnossen, Jeltsje S. [3 ]
Nieuwenhuijzen, Grard A. P. [1 ]
Bloemen, Johanne G. [1 ]
Coolen, Lien [8 ]
Nederend, Joost [8 ]
Peulen, Heike M. U. [3 ]
Rutten, Harm J. T. [1 ,2 ]
Burger, Jacobus W. A. [1 ]
机构
[1] Catharina Hosp, Dept Surg, Eindhoven, Netherlands
[2] Maastricht Univ, Fac Hlth Med & Life Sci, GROW Sch Oncol & Reprod, Maastricht, Netherlands
[3] Catharina Hosp, Dept Radiat Oncol, Eindhoven, Netherlands
[4] Netherlands Canc Inst, Dept Radiat Oncol, Amsterdam, Netherlands
[5] Catharina Hosp, Dept Med Oncol, Eindhoven, Netherlands
[6] Catharina Hosp, Dept Nucl Med, Eindhoven, Netherlands
[7] Catharina Hosp, Dept Pathol, Eurofin PAMM, Eindhoven, Netherlands
[8] Catharina Hosp, Dept Radiol, Eindhoven, Netherlands
[9] Catharina Hosp, Dept Surg, Michelangelolaan 2, NL-5623 EJ Eindhoven, Netherlands
关键词
TOTAL MESORECTAL EXCISION; CLINICAL COMPLETE RESPONDERS; QUALITY-OF-LIFE; PREOPERATIVE CHEMORADIOTHERAPY; INTERNATIONAL WATCH; WAIT DATABASE; OPEN-LABEL; SURGERY; CHEMOTHERAPY; MULTICENTER;
D O I
10.1093/bjs/znad094
中图分类号
R61 [外科手术学];
学科分类号
摘要
This study aimed to evaluate oncological outcomes of patients with locally recurrent rectal cancer with a pCR, and to compare these with the results for patients without a pCR, after completing treatment with curative intent. Patients with a pCR had superior oncological outcomes to those without a pCR. It may be possible to develop some form of a watch-and-wait approach in highly selected patients, to potentially improve quality of life by avoiding extensive surgical procedures, without compromising oncological outcomes. Background For patients with locally recurrent rectal cancer, it is an ongoing pursuit to establish factors predicting or improving oncological outcomes. In locally advanced rectal cancer, a pCR appears to be associated with improved outcomes. The aim of this retrospective cohort study was to compare the oncological outcomes of patients with locally recurrent rectal cancer with and without a pCR. Methods Patients who underwent neoadjuvant treatment and surgery for locally recurrent rectal cancer with curative intent between January 2004 and June 2020 at a tertiary referral hospital were analysed. Primary outcomes included overall survival, disease-free survival, metastasis-free survival, and local re-recurrence-free survival, stratified according to whether the patient had a pCR. Results Of a total of 345 patients, 51 (14.8 per cent) had a pCR. Median follow-up was 36 (i.q.r. 16-60) months. The 3-year overall survival rate was 77 per cent for patients with a pCR and 51.1 per cent for those without (P < 0.001). The 3-year disease-free survival rate was 56 per cent for patients with a pCR and 26.1 per cent for those without (P < 0.001). The 3-year local re-recurrence-free survival rate was 82 and 44 per cent respectively (P < 0.001). Surgical procedures (for example soft tissue, sacrum, and urogenital organ resections) and postoperative complications were comparable between patients with and without a pCR. Conclusion This study showed that patients with a pCR have superior oncological outcomes to those without a pCR. It may therefore be safe to consider a watch-and-wait approach in highly selected patients, potentially improving quality of life by omitting extensive surgical procedures without compromising oncological outcomes.
引用
收藏
页码:950 / 957
页数:8
相关论文
共 35 条
[1]  
[Anonymous], 2021, BJS Open, V5, pzrab010
[2]   Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial [J].
Bahadoer, Renu R. ;
Dijkstra, Esmee A. ;
van Etten, Boudewijn ;
Marijnen, Corrie A. M. ;
Putter, Hein ;
Kranenbarg, Elma Meershoek-Klein ;
Roodvoets, Annet G. H. ;
Nagtegaal, Iris D. ;
Beets-Tan, Regina G. H. ;
Blomqvist, Lennart K. ;
Fokstuen, Tone ;
ten Tije, Albert J. ;
Capdevila, Jaume ;
Hendriks, Mathijs P. ;
Edhemovic, Ibrahim ;
Cervantes, Andres ;
Nilsson, Per J. ;
Glimelius, Bengt ;
van de Velde, Cornelis J. H. ;
Hospers, Geke A. P. .
LANCET ONCOLOGY, 2021, 22 (01) :29-42
[3]   Factors associated with metachronous metastases and survival in locally advanced and recurrent rectal cancer [J].
Baird, D. L. H. ;
Kontovounisios, C. ;
Simillis, C. ;
Pellino, G. ;
Rasheed, S. ;
Tekkis, P. P. .
BJS OPEN, 2020, 4 (06) :1172-1179
[4]  
Cady B, 1997, ARCH SURG-CHICAGO, V132, P338
[5]   Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23) : a multicentre, randomised, open-label, phase 3 trial [J].
Conroy, Thierry ;
Bosset, Jean-Francois ;
Etienne, Pierre-Luc ;
Rio, Emmanuel ;
Francois, Eric ;
Mesgouez-Nebout, Nathalie ;
Vendrely, Veronique ;
Artignan, Xavier ;
Bouche, Olivier ;
Gargot, Dany ;
Boige, Valerie ;
Bonichon-Lamichhane, Nathalie ;
Louvet, Christophe ;
Morand, Clotilde ;
de la Fouchardiere, Christelle ;
Lamfichekh, Najib ;
Juzyna, Beata ;
Jouffroy-Zeller, Claire ;
Rullier, Eric ;
Marchal, Frederic ;
Gourgou, Sophie ;
Castan, Florence ;
Borg, Christophe .
LANCET ONCOLOGY, 2021, 22 (05) :702-715
[6]   Selected stage IV rectal cancer patients managed by the watch-and-wait approach after pelvic radiotherapy: a good alternative to total mesorectal excision surgery? [J].
Custers, Petra A. ;
Hupkens, Britt J. P. ;
Grotenhuis, Brechtje A. ;
Kuhlmann, Koert F. D. ;
Breukink, Stephanie O. ;
Beets, Geerard L. ;
Melenhorst, Jarno .
COLORECTAL DISEASE, 2022, 24 (04) :401-410
[7]   International variation in managing locally advanced or recurrent rectal cancer: prospective benchmark analysis [J].
Denost, Q. ;
Solomon, M. ;
Tuech, J. -J. ;
Ghouti, L. ;
Cotte, E. ;
Panis, Y. ;
Lelong, B. ;
Rouanet, P. ;
Faucheron, J. -L. ;
Jafari, M. ;
Lefevre, J. H. ;
Rullier, E. ;
Heriot, A. ;
Austin, K. ;
Lee, P. ;
Brown, W. ;
Maillou-Martinaud, H. ;
Savel, H. ;
Quintard, B. ;
Broc, G. ;
Saillour-Glenisson, F. .
BRITISH JOURNAL OF SURGERY, 2020, 107 (13) :1846-1854
[8]   A phase III randomized trial evaluating chemotherapy followed by pelvic reirradiation versus chemotherapy alone as preoperative treatment for locally recurrent rectal cancer - GRECCAR 15 trial protocol [J].
Denost, Quentin ;
Frison, Eric ;
Salut, Cecile ;
Sitta, Remy ;
Rullier, Anne ;
Harji, Deena ;
Maillou-Martinaud, Helene ;
Rullier, Eric ;
Smith, Denis ;
Vendrely, Veronique .
COLORECTAL DISEASE, 2021, 23 (07) :1909-1918
[9]   Oncological outcomes of multimodality treatment for patients undergoing surgery for locally recurrent rectal cancer: A systematic review [J].
Fadel, Michael G. ;
Ahmed, Mosab ;
Malietzis, George ;
Pellino, Gianluca ;
Rasheed, Shahnawaz ;
Brown, Gina ;
Tekkis, Paris ;
Kontovounisios, Christos .
CANCER TREATMENT REVIEWS, 2022, 109
[10]   Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study [J].
Fernandez, Laura M. ;
Sao Juliao, Guilherme P. ;
Figueiredo, Nuno L. ;
Beets, Geerard L. ;
van der Valk, Maxime J. M. ;
Bahadoer, Renu R. ;
Hilling, Denise E. ;
Kranenbarg, Elma Meershoek-Klein ;
Roodvoets, Annet G. H. ;
Renehan, Andrew G. ;
van de Velde, Cornelis J. H. ;
Habr-Gama, Angelita ;
Perez, Rodrigo O. .
LANCET ONCOLOGY, 2021, 22 (01) :43-50